By Daniella Parra
Avertix Medical announced that Professor Ian Meredith AM will join the Board of Directors, bringing extensive experience as a renowned interventional cardiologist and global medical executive, the company said.
“Avertix has a meaningful product that holds the potential to empower patients at a time of great anxiety and uncertainty in their lives,” said Professor Meredith. “I can say confidently after 35 years of caring for patients suffering a heart attack, with more than 20 of those as an interventional cardiologist undertaking primary percutaneous coronary intervention (PCI) for their acute heart attack, that the fear of another cardiac event, and resulting death, is profound and often paralyzing to the point that many struggle to return to their normal daily activities, both personally and professionally.”
This follows the company’s business combination with BIOS Acquisition Corp., expected to become a publicly traded company on Nasdaq under the ticker symbol “AVRT” upon completion of the transaction.